Jorge Mena

Dr. Jorge Mena

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LALaura Arnaldo
Laura Arnaldo
JMJorge Mena
Jorge Mena
MSMònica Serradell
Mònica Serradell
CGCarles Gaig
Carles Gaig
DCDavid Adamuz Comino
David Adamuz Comino
KBKatrin Beyer
Katrin Beyer
Individuals diagnosed with isolated REM sleep behavior disorder (IRBD) have a high risk of developing Lewy body disorders (LBD), mainly Parkinson’s disease (PD) or dementia with Lewy bodies (DLB). As we have previously identified seven platelet-derived miRNAs as potential biomarkers for DLB, in this pilot study we aimed to investigate whether specific expression changes of these miRNAs are also present in IRBD. RNA was obtained from platelets of individuals with IRBD (n = 29) and controls (n = 34), and miRNA levels were determined with a miRCURY LNA miRNA Custom PCR Panel. miRNA interactomes of deregulated miRNAs were determined, and mRNA quantification of miRNA target genes was carried out using real-time PCR and the ΔΔCt method. We found that the expression of hsa-miR- 139 - 5p (p = 0.010) and hsa-miR- 142 - 3p (p = 0.017) was diminished, while hsa-miR- 191 - 5p (p = 0.023) was increased in platelets of IRBD patients compared with controls. Interactome analysis of these miRNAs showed that hsa-miR- 142 - 3p regulates genes related to the structure and maintenance of the cytoskeleton. Of the 15 genes expressed in platelets, the expression of WASL, a gene involved in actin filament organization, was increased in platelets of IRBD patients. Additionally, WASL expression correlated inversely with hsa-miR- 142 - 3p expression. Since the interactomes of hsa-miR- 139 - 5p and hsa-miR- 191 - 5p play a role in several cancer types, their expression was not addressed. Changes in hsa-miR- 142 - 3p, hsa-miR- 139 - 5p, and hsa-miR- 191 - 5p expression were found in IRBD platelets and might represent early biomarkers for LBD involving cytoskeleton dysfunction. Increased expression of WASL could indicate that altered platelet activation occurs early during the development of LBD.

16 December 2025 in Brain Pathology
Verified
Journal Article
Open access
Laura Marsal GarcíaLaura Marsal García
Laura Marsal García
JMJorge Mena
Jorge Mena
CLCarol‐Ann Lao
Carol‐Ann Lao
DCDavid Adamuz Comino
David Adamuz Comino
LALaura Arnaldo
Laura Arnaldo
KBKatrin Beyer
Katrin Beyer
The 14‐3‐3 protein family plays a crucial role in cellular signaling and neuronal survival. Although 14‐3‐3 isoforms have been involved in the etiology of some neurodegenerative disorders, their role remains poorly understood in alpha‐synucleinopathies. In this study, we wanted to characterize 14‐3‐3 gene expression patterns in the brain and periphery of patients with Lewy body pathology (LBP). We analyzed messenger RNA (mRNA) expression of all seven 14‐3‐3 isotypes in the temporal cortex and caudate nucleus of brains with pure and common LBP, as well as in cerebrospinal fluid, peripheral blood, and platelets. Stratifin (SFN) protein expression was assessed by immunohistochemistry and enzyme‐linked immunosorbent assay. Effects of SFN overexpression on astrocyte activation were investigated in vitro. In the temporal cortex of LBP patients, six out of seven 14‐3‐3 genes were significantly downregulated, while SFN was markedly up‐regulated. SFN protein localized to neurofibrillary tangles in the parahippocampal region and reactive astrocytes in white matter. In vitro, SFN treatment induced biphasic changes in astrocytic glial fibrillary acidic protein expression, suggesting a role in glial activation. Peripheral analysis revealed no significant 14‐3‐3 mRNA changes in blood, but platelet expression patterns inversely correlated with brain tissue; six isoforms were up‐regulated, and SFN was strongly downregulated in dementia with Lewy bodies (DLB) platelets. Our findings revealed an important shift in 14‐3‐3 isotype expression in the temporal cortex of LBP patients, where SFN up‐regulation reflected its colocalization with tau pathology and astrocytic reactivity. The inverse expression profile in platelets in DLB highlights their potential as accessible biomarkers for molecular changes occurring in the brain.

Verified
Journal Article
Open access
PDF file
LALaura Arnaldo
Laura Arnaldo
JMJorge Mena
Jorge Mena
DCDavid Adamuz Comino
David Adamuz Comino
AMAlex Menéndez
Alex Menéndez
MSMònica Serradell
Mònica Serradell
KBKatrin Beyer
Katrin Beyer
Platelets are increasingly recognized as multifunctional cells with roles extending beyond hemostasis to immune regulation, inflammation, and neurodegeneration. Here, we performed RNA-Seq profiling of platelets from patients with idiopathic REM sleep behavior disorder (IRBD), dementia with Lewy bodies (DLB), Parkinson disease (PD), Alzheimer disease (AD), and healthy controls (CTRLs) to explore disease-specific transcriptomic signatures. Across all groups, the RNA class distribution was similar, dominated by mRNAs (78–80%) and long non-coding RNAs (lncRNAs; 15–16%). DLB platelets displayed a reduced proportion of lncRNAs, suggesting an impaired RNA regulation, whereas IRBD concentrated the highest number of disease-specific lncRNAs, half of which were Y-linked, consistent with the male predominance observed in alpha-synucleinopathies. Differential expression analysis (DEA) revealed extensive transcriptomic remodeling in IRBD and DLB, particularly affecting RNA processing, cytoskeletal organization, and platelet activation pathways, while PD and AD showed minimal changes. These findings suggest a progressive impairment of platelet activation and signaling across the DLB continuum, potentially mirroring neuronal dysfunction. The limited transcriptional deregulation in PD may reflect its pronounced biological heterogeneity, consistent with recent multidimensional disease models. Overall, our study highlights platelets as accessible indicators of early and disease-stage-specific molecular alterations in α-synucleinopathies.

14 October 2026 in Movement Disorders
Verified
Journal Article
Open access
PDF file
SJSusanna Jiménez‐Román
Susanna Jiménez‐Román
DCDavid Adamuz Comino
David Adamuz Comino
JMJorge Mena
Jorge Mena
ATAbril Tuset
Abril Tuset
MMM del Mar Mallo
M del Mar Mallo
KBKatrin Beyer
Katrin Beyer
Click on the article title to read more.